EQ Stock Analysis
EQ
Uncovered
Equillium Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The Company’s initial product candidate, itolizumab (EQ001), is a clinical-stage monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The Company’s pipeline is focused on developing EQ001, EQ101 and EQ102 disease modifying treatments for multiple severe immuno-inflammatory disorders. Its clinical development programs for EQ001 for the treatment of acute graft-versus-host disease (aGVHD) and lupus/lupus nephritis. The firm is in the process of clinical development of EQ101 and EQ102 and to initiate a Phase II study of EQ101 in alopecia areata and a Phase I study of EQ102 in celiac disease. The firm is conducting the EQUATE study, is a Phase Ib clinical study of EQ001 therapy concomitant with steroids for the treatment of aGVHD.